8-K
filed July 2, 2024, 7:59 PM ET
CIK 0001850266
M&A
confidence high
sentiment neutral
materiality 1.00
Akili, Inc.: M&A transaction — Akili completes acquisition by Virtual Therapeutics at $0.4340 per share; stock to be delisted
Akili, Inc.
- Tender offer closed with 69,674,538 shares (88.2%) validly tendered at $0.4340 per share; merger completed July 2, 2024.
- All outstanding shares converted to right to receive Offer Price; company becomes wholly owned subsidiary of Virtual Therapeutics.
- Board of directors resigned; Daniel J. Elenbaas becomes sole director; Matt McIntire named Treasurer and Secretary.
- Nasdaq listing suspended; Form 25 to be filed to delist shares; registration to be terminated on Form 15.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.99
Daniel J. Elenbaas was appointed as Director at Akili, Inc..
- Action
- appointed
- Role
- Director
Exact text from the filing
The sole director of Purchaser immediately prior to the Effective Time was Daniel J. Elenbaas.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.99
Daniel J. Elenbaas was appointed as President at Akili, Inc..
- Action
- appointed
- Role
- President
Exact text from the filing
Daniel J. Elenbaas, serving as President
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.99
Christine Lemke resigned as Director at Akili, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
each of Matthew Franklin, Adam Gazzaley, M.D., Ph.D., Mary Hentges, William “BJ” Jones, Jr., Christine Lemke, W. Edward Martucci II, Ph.D., and John Spinale resigned from the board of directors of the Company.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.99
Mary Hentges resigned as Director at Akili, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
each of Matthew Franklin, Adam Gazzaley, M.D., Ph.D., Mary Hentges, William “BJ” Jones, Jr., Christine Lemke, W. Edward Martucci II, Ph.D., and John Spinale resigned from the board of directors of the Company.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.99
Matt McIntire was appointed as Treasurer and Secretary at Akili, Inc..
- Action
- appointed
- Role
- Treasurer and Secretary
Exact text from the filing
Matt McIntire, serving as Treasurer and Secretary
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.99
William "BJ" Jones, Jr. resigned as Director at Akili, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
each of Matthew Franklin, Adam Gazzaley, M.D., Ph.D., Mary Hentges, William “BJ” Jones, Jr., Christine Lemke, W. Edward Martucci II, Ph.D., and John Spinale resigned from the board of directors of the Company.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.99
W. Edward Martucci II resigned as Director at Akili, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
each of Matthew Franklin, Adam Gazzaley, M.D., Ph.D., Mary Hentges, William “BJ” Jones, Jr., Christine Lemke, W. Edward Martucci II, Ph.D., and John Spinale resigned from the board of directors of the Company.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.99
Matthew Franklin resigned as Director at Akili, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
each of Matthew Franklin, Adam Gazzaley, M.D., Ph.D., Mary Hentges, William “BJ” Jones, Jr., Christine Lemke, W. Edward Martucci II, Ph.D., and John Spinale resigned from the board of directors of the Company.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.99
John Spinale resigned as Director at Akili, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
each of Matthew Franklin, Adam Gazzaley, M.D., Ph.D., Mary Hentges, William “BJ” Jones, Jr., Christine Lemke, W. Edward Martucci II, Ph.D., and John Spinale resigned from the board of directors of the Company.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.99
Adam Gazzaley resigned as Director at Akili, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
each of Matthew Franklin, Adam Gazzaley, M.D., Ph.D., Mary Hentges, William “BJ” Jones, Jr., Christine Lemke, W. Edward Martucci II, Ph.D., and John Spinale resigned from the board of directors of the Company.
View on SEC.gov
M&A Transactions
SEC 8-K Item 2.01/5.01
confidence 0.9
Akili, Inc. underwent a change of control involving Virtual Therapeutics Corporation (Parent) and Alpha Merger Sub, Inc. (Purchaser) for $0.4340 per share (closed 2024-07-02).
- Action
- change of control
- Counterparty
- Virtual Therapeutics Corporation (Parent) and Alpha Merger Sub, Inc. (Purchaser)
- Consideration
- $0.4340 per share
- Closing
- 2024-07-02
Exact text from the filing
offer to purchase all of the C ompany’s outstanding shares of common stock, par value $0.0001 per share (the “ Common Stock ”), for a price per share of the Common Stock of $0.4340 (the “ Offer Price ”), payable subject to any applicable tax withholding and without interest, all subject to and in accordance with the terms and conditions set forth in the
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.